Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 30 Aug 2021
FDA grants breakthrough device designation for ImpediMed's SOZO digital health platform for renal failure
30 August 2021 - FDA recognises potential of SOZO digital health platform to assist clinicians in measuring exact fluid volume of ...
Posted by Michael Wonder on 30 Aug 2021
Australia is ending its zero-covid strategy
28 August 2021 - “This is not a sustainable way to live in this country,” declared Scott Morrison, Australia’s prime minister, ...
Posted by Michael Wonder on 30 Aug 2021
Health Canada approves Myinfla (colchicine 0.5 mg extended release tablets), a new repurposed treatment for cardiovascular disease
27 August 2021 - A unique partnership between Pharmascience and the Montreal Heart Institute leads to the approval of Myinfla (colchicine ...
Posted by Michael Wonder on 30 Aug 2021
Roche to withdraw 2 Parkinson’s drugs from Korean market
27 August 2021 - Roche said it would withdraw Parkinson’s syndrome treatment Madopar 125 mg and 250 mg tablets from ...
Posted by Michael Wonder on 30 Aug 2021
FDA orphan drug approval: Octapharma’s Octagam 10% receives 7 years of market exclusivity for adult dermatomyositis
30 August 2021 - Octagam 10% expected to become the first treatment option for adults with rare immune-mediated inflammatory disease. ...
Posted by Michael Wonder on 30 Aug 2021
Evrysdi (risdiplam) receives CADTH reimbursement recommendation for some patients with spinal muscular atrophy
30 August 2021 - Roche Canada today announced that the CADTH Canadian Drug Expert Committee has issued its final recommendation ...
Posted by Michael Wonder on 30 Aug 2021
Biogen offers free Alzheimer's drug as Medicare payment uncertainty remains
30 August 2021 - Biogen is providing its controversial and expensive new Alzheimer's drug free of charge for some patients amid ...
Posted by Michael Wonder on 30 Aug 2021
Review of the National Medicines Policy – call for submissions
30 August 2021 - The National Medicines Policy Review Committee is now welcoming submissions to support the review of the National Medicines ...
Posted by Michael Wonder on 30 Aug 2021
Public Summary Documents – May 2021 PBAC meeting
27 August 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2021 PBAC ...
Posted by Michael Wonder on 29 Aug 2021
Moderna COVID-19 vaccine gets Health Canada approval for kids 12+
27 August 2021 - As the Delta variant rages through unvaccinated populations in Canada ahead of the back-to-school season, children ...
Posted by Michael Wonder on 29 Aug 2021
COVID-19 vaccine claims scheme
29 August 2021 - Medicines Australia commends the Australian Government on the COVID-19 Vaccine Claim Scheme for anyone who experiences ...
Posted by Michael Wonder on 29 Aug 2021
Breakthrough PBS listings to benefit thousands of Australians
29 August 2021 - From 1 September 2021, thousands of Australians living with schizophrenia, liver disease, lymphoma and anaphylaxis will have ...
Posted by Michael Wonder on 28 Aug 2021
European Medicines Agency grants Marinus Pharmaceuticals accelerated assessment of ganaxolone for treatment of CDKL5 deficiency disorder
26 August 2021 - Marinus Pharmaceuticals today announced that the CHMP of the EMA has granted its request for accelerated ...
Posted by Michael Wonder on 28 Aug 2021
Merck’s Keytruda (pembrolizumab) receives two new approvals in Japan
26 August 2021 - Keytruda now approved for the treatment of patients with PD-L1 positive, hormone receptor negative and HER2 negative, ...
Posted by Michael Wonder on 28 Aug 2021
Incyte and MorphoSys announce the European Commission approval of Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
26 August 2021 - In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory DLBCL. ...